Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Sep 19 - Sep 24
In proof-of-concept studies, NNMT inhibitors (NNMTis) have demonstrated promise as potential treatments for obesity and obesity-related metabolic comorbidities (e.g., T2D, fatty liver) 8,9,13
Ongoing complications linked to GLP-1 exposure, such as inability to tolerate normal meals, chronic weight loss, or reduced work capacity
USA 106 , 2038820393 (2009)
It is also not recommended for patients with existing gastrointestinal disease to avoid potential side effects or exacerbating the condition
US$ 27.50
US$ 20.95
US$ 20.41
US$ 29.84
US$ 20.87
US$ 21.82
